@article{MTMT:34318749, title = {Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study}, url = {https://m2.mtmt.hu/api/publication/34318749}, author = {Andre, Thierry and Falcone, Alfredo and Shparyk, Yaroslav and Moiseenko, Fedor and Polo-Marques, Eduardo and Csoszi, Tibor and Campos-Bragagnoli, Arinilda and Liposits, Gábor and Chmielowska, Ewa and Aubel, Paul and Martin, Lourdes and Fougeray, Ronan and Amellal, Nadia and Saunders, Mark P.}, doi = {10.1016/S2468-1253(22)00334-X}, journal-iso = {LANCET GASTROENT HEPATOL}, journal = {LANCET GASTROENTEROLOGY AND HEPATOLOGY}, volume = {8}, unique-id = {34318749}, issn = {2468-1253}, abstract = {Background Trifluridine-tipiracil plus bevacizumab has shown efficacy in previous phase 2 studies including patients with unresectable metastatic colorectal cancer. We aimed to investigate first-line trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab in patients with unresectable metastatic colorectal cancer ineligible for intensive treatment.Methods In this open-label, randomised, phase 3 study, we enrolled patients aged 18 years and older with histologically confirmed metastatic colorectal cancer, ineligible for full-dose doublet or triplet chemotherapy and curative resection across 25 countries and regions. Participants were randomly allocated (1:1) to trifluridine-tipiracil plus bevacizumab or capecitabine plus bevacizumab until disease progression or unacceptable toxicity using an interactive web response system, stratified by Eastern Cooperative Oncology Group (ECOG) performance status (0 vs 1 vs 2), primary tumour location (right vs left colon), and the main reason for not being a candidate for intensive therapy (clinical condition vs non-clinical condition). The primary endpoint was investigator-assessed progression-free survival, defined as the time from randomisation to radiological progression or death from any cause, in the intention-to-treat population. Safety was assessed in all patients having taken at least one dose of the study drug. The trial is ongoing, findings presented here are those of the primary analysis of progression-free survival, conducted after 629 events had occurred. This study is registered with ClinicalTrials.gov, NCT03869892.Findings Between March 21, 2019, and Sept 14, 2020, 856 patients (54% male, 46% female) were randomly assigned to trifluridine-tipiracil plus bevacizumab (n=426) or capecitabine plus bevacizumab (n=430). After a median follow-up of 16 center dot 6 months (95% CI 16 center dot 5-17 center dot 1), the hazard ratio for progression-free survival for trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab was 0 center dot 87 (0 center dot 75-1 center dot 02; p=0 center dot 0464; protocol-defined significance level of p=0 center dot 021 not met). Investigator-assessed median progression-free survival was 9 center dot 4 months (95% CI 9 center dot 1-10 center dot 9) with trifluridine-tipiracil plus bevacizumab versus 9 center dot 3 months (8 center dot 9-9 center dot 8) with capecitabine plus bevacizumab. The most common grade 3 and higher treatment-emergent adverse events were neutropenia (220 [52%] of 423 patients in the trifluridine-tipiracil plus bevacizumab group vs six [1%] of 427 in the capecitabine plus bevacizumab group), decreased neutrophil count (78 [18%] vs four [<1%]), anaemia (60 [14%] vs 16 [4%]), and hand-foot syndrome (none vs 61 [15%]). Nine deaths (five in the trifluridine-tipiracil plus bevacizumab group and four in the capecitabine plus bevacizumab group) were treatment related.Interpretation First-line trifluridine-tipiracil plus bevacizumab was not superior to capecitabine plus bevacizumab in this population. As expected, the safety profile differed between the two treatments, but there were no new safety concerns. Trifluridine-tipiracil plus bevacizumab represents a feasible alternative to capecitabine plus bevacizumab in this population.Copyright (c) 2022 Elsevier Ltd. All rights reserved.}, year = {2023}, eissn = {2468-1253}, pages = {133-144}, orcid-numbers = {Moiseenko, Fedor/0000-0003-2544-9042; Liposits, Gábor/0000-0002-8204-3949} } @article{MTMT:33314218, title = {Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the Young International Society of Geriatric Oncology}, url = {https://m2.mtmt.hu/api/publication/33314218}, author = {Baxter, Mark A. and Marinho, Joana and Soto-Perez-de-Celis, Enrique and Rodriquenz, Maria Grazia and Arora, Sukeshi Patel and Lok, Wendy Chan Wing and Shih, Yung-Yu and Liposits, Gábor and O'Hanlon, Shane and Petty, Russell D.}, doi = {10.1016/j.jgo.2021.09.006}, journal-iso = {J GERIATR ONCOL}, journal = {JOURNAL OF GERIATRIC ONCOLOGY}, volume = {13}, unique-id = {33314218}, issn = {1879-4068}, abstract = {Gastroesophageal adenocarcinoma is a disease of older adults with very poor survival rates. Its incidence has risen dramatically across the world in recent decades. Current treatment approaches for older adults are based largely on extrapolated evidence from clinical trials conducted in younger and fitter participants than those more commonly encountered in clinical practice. Understanding how to apply available evidence to our patients in the clinic setting is essential given the high morbidity of both curative and palliative treatment. This review aims to use available data to inform the management of an older adult with gastroesophageal adenocarcinoma . (c) 2021 Elsevier Ltd. All rights reserved.}, keywords = {TOXICITY; Multi-disciplinary; Real-world; Frailty; Gastroesophageal adenocarcinoma}, year = {2022}, eissn = {1879-4076}, pages = {7-19}, orcid-numbers = {Liposits, Gábor/0000-0002-8204-3949; O'Hanlon, Shane/0000-0002-9270-2768} } @article{MTMT:2591228, title = {Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer}, url = {https://m2.mtmt.hu/api/publication/2591228}, author = {Rasmussen, Maja Lynge and Liposits, Gábor and Yogendram, Subethini and Jensen, Anders Bonde and Linnet, Søren and Langkjer, Sven Tyge}, doi = {10.3109/0284186X.2014.918277}, journal-iso = {ACTA ONCOL}, journal = {ACTA ONCOLOGICA}, volume = {2014}, unique-id = {2591228}, issn = {0284-186X}, abstract = {Maja Lynge Rasmussen 1 , 2 , 1 , 1 , S Ø Ren Linnet 2 &}, year = {2014}, eissn = {1651-226X}, pages = {9-1275}, orcid-numbers = {Liposits, Gábor/0000-0002-8204-3949} } @book{MTMT:2565086, title = {Sugárterápia}, url = {https://m2.mtmt.hu/api/publication/2565086}, isbn = {9789632264530}, author = {Cselik, Zsolt and Hadjiev, Janaki and Horváth, Ákos and Jánváry, Zsolt Levente and Kovács, Árpád and Liposits, Gábor and Vallyon, Márta and Mangel, László and Antal, Gergely}, editor = {Kovács, Árpád and Hadjiev, Janaki and Horváth, Ákos}, publisher = {Medicina Kiadó Zrt.}, unique-id = {2565086}, year = {2014}, orcid-numbers = {Cselik, Zsolt/0000-0003-2090-4632; Hadjiev, Janaki/0000-0003-4419-353X; Jánváry, Zsolt Levente/0000-0002-4583-4901; Kovács, Árpád/0000-0002-8469-5764; Liposits, Gábor/0000-0002-8204-3949; Antal, Gergely/0000-0002-9259-6643; Kovács, Árpád/0000-0002-8469-5764; Hadjiev, Janaki/0000-0003-4419-353X} } @article{MTMT:2504062, title = {Indukciós kemoterápia és modern PET-CT-MR alapú 3D kemo-radioterápia szerepe a lokálisan előrehaladott fej-nyak tumoros betegek kezelésében. Prospektív klinikai vizsgálat korai tapasztalatai}, url = {https://m2.mtmt.hu/api/publication/2504062}, author = {Somogyiné Ezer, Éva and Kovács, Árpád and Liposits, Gábor and Antal, Gergely and Gilincsek, Lajos and Zádori, Péter and Repa, Imre}, journal-iso = {MAGYAR ONKOLÓGIA}, journal = {MAGYAR ONKOLÓGIA}, volume = {57}, unique-id = {2504062}, issn = {0025-0244}, abstract = {Magyar Onkológusok Társaságának 30. kongresszusa. Pécs, 2013. november 14–16.}, year = {2013}, eissn = {2060-0399}, pages = {81-81}, orcid-numbers = {Kovács, Árpád/0000-0002-8469-5764; Liposits, Gábor/0000-0002-8204-3949; Antal, Gergely/0000-0002-9259-6643; Zádori, Péter/0000-0003-2200-665X} } @article{MTMT:2482295, title = {Treatment with Eribulin (Halaven) in heavily pre-treated patients with metastatic breast cancer}, url = {https://m2.mtmt.hu/api/publication/2482295}, author = {Lynge, Maja and Liposits, Gábor and Linnet, Søren and Langkjer, Sven Tyge}, doi = {10.1016/S0960-9776(13)70082-1}, journal-iso = {BREAST}, journal = {BREAST}, volume = {22}, unique-id = {2482295}, issn = {0960-9776}, year = {2013}, eissn = {1532-3080}, pages = {S43-S43}, orcid-numbers = {Liposits, Gábor/0000-0002-8204-3949} } @article{MTMT:2340412, title = {Radiotherapy of distant metastases. An overview}, url = {https://m2.mtmt.hu/api/publication/2340412}, author = {Kovács, Árpád and Benkő, András and Liposits, Gábor and Vandulek, Csaba}, journal-iso = {INT J CANCER RES PREV}, journal = {INTERNATIONAL JOURNAL OF CANCER RESEARCH AND PREVENTION}, volume = {5}, unique-id = {2340412}, issn = {1554-1134}, abstract = {Cancer related morbidity and mortality are two of the most important health care problems in the modern world. In general, the number of newly diagnosed cancer patients is increasing year by year. With the development of tumor treatment modalities (new surgery techniques, modern combined chemotherapy, sophisticated 3-4D based radiotherapy, and newly developed biological-immunotherapy modalities) in most cancer types longer survival (overall, disease free, and relapsus free) can be reached. In the natural course of invasive cancers, the possibility of the presentation of distant metastases is high. Invasive cancers have the property of vascular and lymphatic invasion and tumor cells can invade into distant organs and form metastases. The most frequent localizations of distant metastases are the followings: brain, bone, liver, lung, and lymph nodes (not regional). There are several possible modalities to be used in the treatment of distant metastases: surgery, chemotherapy, interventional methods, radiotherapy, radiosurgery, etc. In this chapter we give a general overview of the modern radiotherapy of the most frequent distant metastases, especially focusing on new trends, techniques and methods, and a general view of the latest literature. © Nova Science Publishers, Inc.}, year = {2012}, pages = {89-110}, orcid-numbers = {Kovács, Árpád/0000-0002-8469-5764; Liposits, Gábor/0000-0002-8204-3949; Vandulek, Csaba/0000-0001-5940-3603} } @article{MTMT:2209285, title = {Treatment of head-neck cancer patients using conpas techniquer. 2 years follow up results}, url = {https://m2.mtmt.hu/api/publication/2209285}, author = {Kovács, Árpád and Antal, Gergely and Glavák, Csaba and Hadjiev, Janaki and Liposits, Gábor and Vandulek, Csaba and Lakosi, Ferenc and Colen, Rivka C. and Repa, Imre}, doi = {10.1016/S0167-8140(12)71516-5}, journal-iso = {RADIOTHER ONCOL}, journal = {RADIOTHERAPY AND ONCOLOGY}, volume = {103}, unique-id = {2209285}, issn = {0167-8140}, year = {2012}, eissn = {1879-0887}, pages = {S455-S455}, orcid-numbers = {Kovács, Árpád/0000-0002-8469-5764; Antal, Gergely/0000-0002-9259-6643; Glavák, Csaba/0000-0003-1448-810X; Hadjiev, Janaki/0000-0003-4419-353X; Liposits, Gábor/0000-0002-8204-3949; Vandulek, Csaba/0000-0001-5940-3603} } @{MTMT:1986594, title = {Radiotherapy of distant metastases. an overview}, url = {https://m2.mtmt.hu/api/publication/1986594}, author = {Kovács, Árpád and Benkő, András and Liposits, Gábor and Vandulek, Csaba}, booktitle = {Horizons in cancer research}, unique-id = {1986594}, year = {2012}, pages = {89-109}, orcid-numbers = {Kovács, Árpád/0000-0002-8469-5764; Liposits, Gábor/0000-0002-8204-3949; Vandulek, Csaba/0000-0001-5940-3603} } @article{MTMT:1629108, title = {Technical feasibility of transperineal MR-guided prostate interventions in a low field open MR system: canine study}, url = {https://m2.mtmt.hu/api/publication/1629108}, author = {Kovács, Árpád and Antal, Gergely and Glavák, Csaba and Hadjiev, Janaki and Liposits, Gábor and Vandulek, Csaba and Lakosi, Ferenc and Colen, Rivka R and Repa, Imre}, journal-iso = {RADIOTHER ONCOL}, journal = {RADIOTHERAPY AND ONCOLOGY}, volume = {103}, unique-id = {1629108}, issn = {0167-8140}, year = {2012}, eissn = {1879-0887}, pages = {S460-S460}, orcid-numbers = {Kovács, Árpád/0000-0002-8469-5764; Antal, Gergely/0000-0002-9259-6643; Glavák, Csaba/0000-0003-1448-810X; Hadjiev, Janaki/0000-0003-4419-353X; Liposits, Gábor/0000-0002-8204-3949; Vandulek, Csaba/0000-0001-5940-3603} }